Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model

Journal of Clinical Oncology

Volumn 27, Issue 19, 2009, Pages 3148-3153

  Chugh, Rashmi ^a   Wathen, J Kyle ^a   Maki, Robert G ^a   Benjamin, Robert S ^a   Patel, Shreyaskumar R ^a   Myers, Paul A ^a   Priebat, Dennis A ^a   Reinke, Denise K ^a   Thomas, Dafydd G ^a   Keohan, Mary L ^a   Samuels, Brian L ^a   Baker, Laurence H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANGIOSARCOMA; ARTICLE; BAYES THEOREM; CANCER PATIENT; CLINICAL TRIAL; DRUG EFFICACY; EWING SARCOMA; FEMALE; FIBROSARCOMA; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MULTICENTER STUDY; NERVE SHEATH TUMOR; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RARE DISEASE; RHABDOMYOSARCOMA; SARCOMA; SIGNAL TRANSDUCTION; STATISTICAL MODEL; SYNOVIAL SARCOMA; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BAYES THEOREM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES; SARCOMA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67650302850     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.5054     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
2. Demetri GD, Elias AD: Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 9:765-785, 1995
3. Lorigan P, Verweij J, Papai Z, et al: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 25:3144-3150, 2007
4. Bramwell VH, Anderson D, Charette ML: Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 4:CD003293, 2001
5. Coindre JM, Terrier P, Bui NB, et al: Prognostic factors in adult patients with locally controlled soft tissue sarcoma: A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 14:869-877, 1996
6. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
7. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004
8. Buchdunger E, Zimmermann J, Mett H, et al: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104, 1996
9. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996
10. Heinrich MC, Griffith DJ, Druker BJ, et al: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932, 2000
11. Thall PF, Wathen JK, Bekele BN, et al: Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med 22:763-780, 2003
12. Goodman SN: Toward evidence-based medical statistics: 1. The P value fallacy. Ann Intern Med 130:995-1004, 1999
13. Goodman SN: Toward evidence-based medical statistics: 2. The Bayes factor. Ann Intern Med 130:1005-1013, 1999
14. Berry DA: Statistics: A Bayesian perspective. Belmont, CA, Duxbury Press, 1995
15. Berry DA: Bayesian clinical trials. Nat Rev Drug Discov 5:27-36, 2006
16. Spiegelhalter D, Thomas A, Best N: Bayesian Inference Using Gibbs Sampling Manual (BUGS 0.5). Cambridge, United Kingdom, MRC Biostatistics Unit, 1995
17. Venables WN, Ripley BD: Modern Applied Statistics with S-plus (ed 3). New York, NY, Springer, 1999
18. Wang S, Saboorian MH, Frenkel E, et al: Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 53:374-381, 2000
19. Yantiss RK, Rosenberg AE, Sarran L, et al: Multiple gastrointestinal stromal tumors in type I neurofibromatosis: A pathologic and molecular study. Mod Pathol 18:475-484, 2005
20. Wei S, Liang Z, Gao J, et al: Patterns of K-ras codon 12 and 13 mutations found in pancreatic adenocarcinoma of 30 Chinese patients by microdissection, PCR and direct sequencing. J Gastroenterol Hepatol 20:67-72, 2005
21. McHugh JB, Thomas DG, Herman JM, et al: Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons. Cancer 107:554-562, 2006
22. Bond M, Bernstein ML, Pappo A, et al: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 50:254-258, 2008
23. Verweij J, van Oosterom A, Blay JY, et al: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006-2011, 2003
24. Schlemmer M, Reichardt P, Verweij J, et al: Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 44:2433-2436, 2008
25. Casper ES, Waltzman RJ, Schwartz GK, et al: Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest 16:442-446, 1998
26. Skubitz KM, Haddad PA: Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104:361-366, 2005
27. Van Glabbeke M, Verweij J, Judson I, et al: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38:543-549, 2002
28. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003
29. Debiec-Rychter M, Sciot R, Le Cesne A, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103, 2006